Arcturus Therapeutics ARCT 深 沪
等待开盘 08-18 09:30:00 美东时间
19.48
+0.250
+1.30%
华盛通- 最 高19.7897
- 今 开19.21
- 成交量 99.41万股
- 最 低 18.81
- 昨 收 19.23
- 总市值 5.29亿
- 52周最高 25.88
- 市盈率 静 --
- 换手率 3.66%
- 52周最低 8.04
- 委 比 60.65%
- 总股本 2715.45万
- 历史最高 129.71
- 量 比 0.72
- 振 幅 5.09%
- 历史最低 4.11
- 每 手 1
- 风险率 3.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray涨超30%
加密货币交易所Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray隔夜涨超30%，周内涨超90%，特朗普拟将大麻改为低危药物>>
08-14 15:08
美股牛股 | 多只绩优股狂飙！Rumbleon涨超60%，Tonix制药控股涨超32%
多只绩优股狂飙！Rumbleon涨超60%，Tonix制药控股涨超32%；美国7月机票价格创3年多来最大月度涨幅！美国航空股Frontier Group涨近30%>>
08-13 15:56
Arcturus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
4 analysts have expressed a variety of opinions on Arcturus Therapeutics (NASDA...
08-12 21:01
Citigroup Maintains Buy on Arcturus Therapeutics, Raises Price Target to $49
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target from $47 to $49.
08-12 19:31
Arcturus Therapeutics Q2 EPS $(0.34) Beats $(0.96) Estimate, Sales $28.301M Beat $22.435M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.96) by 64.58 percent. This is a 46.88 percent increase over losses of $(0.64) per share
08-12 04:09
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News
https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research
08-05 00:40
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report second quarter 2025 financial results and provide a business update on August 6, 2025. A conference call and webcast will be held at 4:30 p.m. ET the same day, and the webcast will be available on the Company’s website. Arcutis focuses on developing innovative treatments for immune-mediated dermatological diseases with a portfolio of advanced targeted topicals.
07-23 20:00
中信博与上海电气签署沙特2.3GW光伏项目大单，持续领跑中东市场
日前，中信博与上海电气正式签署沙特Sadawi光伏项目合作订单，项目容量2.3GW。上海电气电站工程公司总经理裘名华，中信博董事长蔡浩、高级副总裁周石俊等共同见...
07-17 09:54
William Blair Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)
In a report released today, Myles Minter from William Blair reiterated a Buy ra...
07-06 01:55
